Key result
Red ginseng prevented the decrease in left ventricular ejection fraction, prolonged survival, and reduced cardiomyocyte damage in a mouse model of doxorubicin-induced cardiomyopathy.
Why the study?
Doxorubicin-induced cardiomyopathy carries a poor prognosis without effective therapeutic drugs, and the detailed efficacy of antioxidant red ginseng in chronic disease models remains unexamined.
Does red ginseng prevent left ventricular ejection fraction decrease and prolong survival in a mouse model of chronic doxorubicin-induced cardiomyopathy?
Does red ginseng prevent left ventricular ejection fraction decrease and prolong survival in a mouse model of chronic doxorubicin-induced cardiomyopathy?
Red ginseng demonstrates potential as a therapeutic candidate for doxorubicin-induced cardiomyopathy by preserving cardiac function and prolonging survival in a preclinical mouse model.
Animal data on red ginseng in DICM warrant clinical caution; leaves open human efficacy trials.
Doxorubicin‐induced cardiomyopathy (DICM) is associated with a poor prognosis, and effective therapeutic drug candidates have yet to be identified. Furthermore, whether basic animal models reflect the clinical pathogenesis of DICM should be carefully examined. Although the exact mechanisms underlying the development of DICM are complex and remain unclear, oxidative stress is strongly implicated as a contributing factor. Therefore, we investigated the effects of ginseng (the root of Panax ginseng : Gin), an inexpensive and safe drug with antioxidant properties. We previously conducted a meta‐analysis that yielded results suggesting its efficacy in humans. However, this study did not examine the efficacy of ginseng in detail. Therefore, this study investigated the efficacy of red ginseng (steamed and dried ginseng cultivated for over six years; RGin) in a mouse model of chronic DICM to elucidate its potential therapeutic benefits. RGin prevented the decrease in left ventricular ejection fraction associated with doxorubicin (DXR) administration and prolonged survival in DBA/2 mice. In addition, RGin reduced DXR‐induced cardiomyocyte damage. These findings highlight its potential as a therapeutic option for the treatment of DICM.
No takes yet. Share an insight, caveat, or question.
Yoshikawa et al. (2023) studied Chronic Doxorubicin-Induced Cardiomyopathy. Red ginseng was evaluated on Left ventricular ejection fraction, survival, and cardiomyocyte damage. Red ginseng prevented the decrease in left ventricular ejection fraction, prolonged survival, and reduced cardiomyocyte damage in a mouse model of doxorubicin-induced cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: